Cogent Biosciences, Inc.
COGT Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$31.21
KIRA · Stoqly’s AI analyst, in plain words
- Cogent Biosciences, Inc. lost $329M in fiscal 2025.
- Free cash flow was −$266M in fiscal 2025, — of revenue.
- Cogent Biosciences, Inc. has $678M more cash than debt.
Market cap
$5.3B
P/E
—
Revenue
—
Net income
−$329M
Free cash flow
−$266M
Operating margin
—
Cogent Biosciences, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$329M
No. It lost money last year.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Cogent Biosciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 17, 2026
- Legal name
- Cogent Biosciences, Inc.
- CIK
- 0001622229
Cogent Biosciences, Inc. · COGT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$72.3M | −$140M | −$192M | −$256M | −$329M |
| Diluted EPS | −$1.87 | −$1.73 | −$1.94 | −$1.94 | −$2.16 |
| Cash | |||||
| Cash from operations | −$58.8M | −$119M | −$154M | −$208M | −$264M |
| Capital expenditure | $1.7M | $6.9M | $2.8M | $0.6M | $1.6M |
| Free cash flow | −$60.5M | −$126M | −$156M | −$208M | −$266M |
| Share count change | 249.5% | 51.7% | 35.6% | 30.4% | 24.1% |
| Debt and strength | |||||
| Cash and short-term investments | $220M | $259M | $266M | $287M | $901M |
| Debt incl. finance leases | — | — | — | $0.0M | $223M |
| Shareholders' equity | $214M | $256M | $258M | $256M | $636M |
| Current ratio | 13.0x | 9.9x | 7.1x | 5.3x | 14.2x |
| Interest coverage | — | — | — | — | −108.9x |
| Returns and quality | |||||
| Return on equity | −32.2% | −59.7% | −74.9% | −99.5% | −73.7% |
| Return on tangible equity | −33.7% | −54.8% | −74.6% | −99.8% | −51.7% |
| Piotroski F-score | — | — | — | — | 3 |
| Altman Z'' | 12.4 | 3.4 | −1.0 | −5.6 | 1.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$384M
6 insiders
Of sales under plans
0%
$1.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cogent Biosciences, Inc. · COGT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $31.21 a share, the company is worth $5.3B.
Source: SEC EDGAR XBRL filings (CIK 0001622229). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.